Search

Your search keyword '"Mitsuteru Kitade"' showing total 150 results

Search Constraints

Start Over You searched for: Author "Mitsuteru Kitade" Remove constraint Author: "Mitsuteru Kitade"
150 results on '"Mitsuteru Kitade"'

Search Results

1. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma

2. Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection

3. Calcified mucinous adenocarcinoma of the stomach metastatic to the iris: a case report

4. Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats

5. Treatment of long-segment Barrett’s adenocarcinoma by complete circular endoscopic submucosal dissection: a case report

6. Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis

7. Hydralazine Sensitizes to the Antifibrotic Effect of 5-Aza-2′-deoxycytidine in Hepatic Stellate Cells

8. Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis

9. Exogenous Administration of Low-Dose Lipopolysaccharide Potentiates Liver Fibrosis in a Choline-Deficient l-Amino-Acid-Defined Diet-Induced Murine Steatohepatitis Model

10. Data Supplement from Antitumor Effects in Hepatocarcinoma of Isoform-Selective Inhibition of HDAC2

11. Supplementary Figures 1-3, Tables 1-3, Methods from Definition of Ubiquitination Modulator COP1 as a Novel Therapeutic Target in Human Hepatocellular Carcinoma

13. Supplementary Figures S1-S7 from MYC Activates Stem-like Cell Potential in Hepatocarcinoma by a p53-Dependent Mechanism

14. Endotoxin Activity Reflects an Increase in Body Temperature in Cirrhotic Patients With Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy

15. Gut dysbiosis associated with clinical prognosis of patients with primary biliary cholangitis

16. Acylcarnitine: Useful biomarker for early diagnosis of hepatocellular carcinoma in non-steatohepatitis patients

17. Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase‐4 inhibitor on hepatic fibrosis

18. Identification of clinical risk factors for histological progression of primary biliary cholangitis

19. Efficacy of L-carnitine on ribavirin-induced hemolytic anemia in patients with hepatitis C virus infection

20. Novel oral plasminogen activator inhibitor‑1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats

21. Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis

22. Comparison of Ablation Area and Change in Functional Liver Reserve after Radiofrequency Ablation for Hepatocellular Carcinoma Using the arfa® and VIVA® Systems

23. Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats

24. Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis

25. Angiotensin receptor blockade attenuates cholangiocarcinoma cell growth by inhibiting the oncogenic activity of Yes-associated protein

26. Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma

27. Glycogenic Hepatopathy in Type 1 Diabetes Mellitus

28. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake

29. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity

30. Periostin cross-reacts with the renin-angiotensin system during liver fibrosis development

31. Combined treatment with dipeptidyl peptidase-4 inhibitor (sitagliptin) and angiotensin-II type 1 receptor blocker (losartan) suppresses progression in a non-diabetic rat model of steatohepatitis

32. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma

33. Calcified mucinous adenocarcinoma of the stomach metastatic to the iris: a case report

34. ADAMTS13 and von Willebrand factor are useful biomarkers for sorafenib treatment efficiency in patients with hepatocellular carcinoma

35. Predictive parameter of tolvaptan effectiveness in cirrhotic ascites

36. Liver fibrosis progression predicts survival in patients with primary biliary cirrhosis

37. Relationship between hepatic progenitor cell-mediated liver regeneration and non-parenchymal cells

38. Bile Acid Sequestrant, Sevelamer Ameliorates Hepatic Fibrosis with Reduced Overload of Endogenous Lipopolysaccharide in Experimental Nonalcoholic Steatohepatitis

39. Hydralazine Sensitizes to the Antifibrotic Effect of 5-Aza-2′-deoxycytidine in Hepatic Stellate Cells

40. Blocking development of liver fibrosis augments hepatic progenitor cell-derived liver regeneration in a mouse chronic liver injury model

41. Efficacy and tolerability of interferon‑free regimen for patients with genotype‑1 HCV infection

42. Proton pump inhibitor therapy does not increase serum endotoxin activity in patients with cirrhosis

43. [Short-term sustained virological response in a patient with liver cirrhosis, hepatitis C, and declining hepatic spare ability during treatment with direct-acting antivirals]

44. Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis

45. von Willebrand factor is a useful biomarker for liver fibrosis and prediction of hepatocellular carcinoma development in patients with hepatitis B and C

46. Additional file 1: of Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats

47. Sulforaphane Inhibits Liver Cancer Cell Growth and Angiogenesis

48. Additional file 2: of Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats

49. Additional file 3: of Acyclic retinoid and angiotensin-II receptor blocker exert a combined protective effect against diethylnitrosamine-induced hepatocarcinogenesis in diabetic OLETF rats

50. FRI-342-Combining probiotics and an angiotensin-2 type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis

Catalog

Books, media, physical & digital resources